Eli Lilly (LLY): FY24 Q3 earnings call, Oct 30, 2024
No Kalshi or Polymarket word markets were listed for Eli Lilly’s Oct 30, 2024 earnings call (FY24 Q3). The transcript is searchable below (quotes of at most 25 words).
UpdatedTranscript
quotes of at most 25 wordsSpeaker-labelled transcript · Source and credits · Used to count words; quotes of at most 25 words.
6 matches for “LillyDirect”; 5 quoted, at least 25 words apart.
…are available for order from Lilly in both the wholesale channel and LillyDirect Pharmacy Solutions. The launch of a single-dose Zepbound vials in the U.S.…
…early days of launching single-dose Zepbound vials in the U.S. exclusively through LillyDirect. 2.5 milligram and 5-milligram single-dose vials are currently available to self-pay patient…
…think out loud, could the launch of cash-pay single vial option via LillyDirect have impacted channels' interest in filling out their inventory given how those…
Well, overall, we launched LillyDirect self-pay by just a month ago. Not we are pleased with the uptake, but we also realized that it takes…
…be defined as being at the low-single to single-digit level. We expect Lilly Direct self-pay though to be a very important channel to grow new…
Agents: this page as TSV at /api/v1/appearances/eli-lilly:2024-10-30:earnings_call · words: /api/v1/brief?appearance=eli-lilly:2024-10-30:earnings_call · columnar JSON in #parrot-data · llms.txt · MCP